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a b s t r a c t
Damage from myocardial infarction (MI) and subsequent heart failure are serious public health concerns.
Current clinical treatments and therapies to treat MI damage largely do not address the regeneration of
cardiomyocytes. In a previous study, we established that it is possible to promote regeneration of cardiac
muscle with vascular endothelial growth factor B gene delivery directly to the ischemic myocardium. In
the current study we aim to optimize cardioporation parameters to increase expression efficiency by
varying electrode configuration, applied voltage, pulse length, and plasmid vector size. By using a surface
monopolar electrode, optimized pulsing conditions and reducing vector size, we were able to prevent
ventricular fibrillation, increase survival, reduce tissue damage, and significantly increase gene expres-
sion levels.
 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
An estimated of 92.1 million adults have at least one type of car-
diovascular disease (CVD) in the United States. In 2013, the most
common underlying reason of death was reported as CVD [1].
The first leading cause of death remained the same in the recent
years (2015–2016) as heart disease and 17.6 million deaths were
attributed to CVD globally [2], until Covid-19. Myocardial infarc-
tion (MI) occurs in about 790,000 people in the United States every
year. 580,000 of these are a first time MI and 210,000 recorded
from the cases who already had a first MI [1]. The 5-year survival
rate remains low [1]. Unfortunately, the heart has insufficient
regenerative capacity; cardiomyocytes do not return. Instead, car-
diac fibroblast proliferation, infiltration and creation of collage-
nous, non-contractile scar tissue replaces cardiomyocytes,
resulting in a thin myocardial wall unable to pump enough blood
to meet the demand and leading to lower quality of life and heart
failure [3]. Current clinical therapies do not regenerate cardiac
myocardium [4,5], however cardiomyocyte proliferation is possi-
ble [6].
Current conventional therapies for acute MI includes pharma-
cological agents such as beta blockers, statins, and angiotensin-
converting-enzyme inhibitors. These are useful in mitigating MI
symptoms and modestly improve long term prognosis but are
unable to repair the infarcted tissue. Because the cardiac dysfunc-
tion remains an issue, there is a great scientific research effort
being spent on finding new approaches focusing on stimulating
angiogenesis, promoting myocardial regeneration, and further
improving the clinical outcomes [4,5].
On-going research to regenerate cardiomyocytes includes many
different methods, though cell and gene therapies are some of the
most common methods. Cell therapies have been approved for
clinical trials, however cell loss can occur within days and thus a
large number of cells are required [5]. One of the most successful
studies within this category required very high cell injection dose
(100 million cells) and resulted in modest cardiac performance
(4% EF) [5]. While currently there are many clinical trials on-
going, cell therapies for treatment of MI are still being optimized,
including the inclusion of biomaterials and/or proteins such as
growth factors to aid the therapy [7,8].
Gene therapies (and more widely, growth factor therapies) are
another commonly researched method to treat MI. Briefly, gene
therapies for MI have not yet been approved [9]. Many target genes
have been investigated, including VEGF-A, which was able to
induce angiogenesis, however the resulting vasculature was not
fully functional [9]. Recent studies, however, have showed
https://doi.org/10.1016/j.bioelechem.2021.107892
1567-5394/ 2021 The Author(s). Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
Bioelectrochemistry 142 (2021) 107892
Contents lists available at ScienceDirect
Bioelectrochemistry
journal homepage: www.elsevier .com/locate /b ioelechemELSEVIER 
promising preliminary results using vascular endothelial growth
factor B (VEGF-B), thoughmore investigation in larger animal mod-
els is warranted [10,11]. Currently, the biggest challenge facing
gene therapy for cardiac applications is seemingly the delivery of
the transgenes [9]. Viral vectors have safety concerns and can
induce unwanted effects such as inflammation [9]. Non-viral gene
delivery methods, including naked plasmid delivery, tend to have
gene expression levels too low to be considered clinically thera-
peutic [9]. In summary, delivery methods of gene therapy need
to be improved and then tested in the appropriate models before
gene therapy can be utilized for the treatment of MI [9].
In a previous study, we determined that gene electrotransfer to
ischemic myocardium could deliver plasmid DNA encoding VEGF-
B, which in turn induced cardiac myocyte proliferation and
renewal at the site of myocardial ischemia [10]. One challenge that
we discovered in our previous work, is that while cardiomyogene-
sis post ischemia can be induced in detectable quantities, these
quantities are still very low, and not clinically useful. Therefore,
the aim of the current work, is to improve exogenous gene expres-
sion levels in the heart.
Gene electrotransfer is an established physical method for gene
delivery to various tissues of the body including the heart [10,12–
14]. Typically, optimal gene expression parameters are determined
empirically, and vary from tissue to tissue. Parameters that work
for gene delivery to the skin, may not work for gene delivery to
the skeletal muscle and vice versa[14–19]. We introduce a new
term – cardioporation – defined specifically as gene electrotransfer
mediated delivery to the myocardium. Cardioporation was first
attempted in a beating pig heart, and further studied in rat beating
hearts [10,12,13,20,21]. Current study extensively explores differ-
ent parameters that lead to improved protein expression levels of
reporter genes, while minimizing tissue damage, ventricular fibril-
lation, and maximizing delivery efficiency.
Previous studies focused on cardioporation feasibility, and
therefore little optimization work was done. Myocardial damage
assessment has not been reported. Cardioparation included using
custom built 4-needle bipolar electrodes and injecting plasmid
DNA and the electrode needles directly into the beating myocar-
dium [10,12,13]. These bipolar electrodes work similarly to bipolar
cauteries, where the active and return electrodes are placed closely
so that the electric field is applied locally within or around the tis-
sue of interest [22]. Similar to cauteries, monopolar electrode
options exist for GET, where the active electrode is placed on the
tissue of interest, and the return electrode is a plate placed some-
where else on the body [22]. In the current study, we have assessed
less invasive options including a surface, monopolar electrode,
pulsing parameters, plasmid DNA injection technique, and plasmid
vector size. Resulting cardioporation method is efficient in reporter
Fig. 1. Intramyocardial injection of 100 lL of plasmid DNA significantly damages myocardium. (A) Experimental timeline, with cardioporation or injection only on day 0,
and imaging on days 1, 2, 5, 7, 10, 14, 21, 28, 35, 42, 49 and 56. (B) No significant differences in expression were observed over 56 days (note background subtraction was
performed, thus there are detectable levels of expression through day 56). Immunofluorescence staining for DDK tag, and counterstaining for cardiac troponin I, show similar
expression distribution, as well as notable damage from plasmid DNA injections of 100 lL bolus intramyocardial injection.
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gene delivery to a beating heart in a rat model. Future work will
focus on therapeutic gene delivery and cardiomyocyte
regeneration.
2. Materials and methods
2.1. Animals
All rat studies followed an approved Old Dominion University
Institutional Animal Care and Use Committee protocol, in accor-
dance with the Guide for the Care and Use of Laboratory Animals
at an AAALAC accredited facility. Animals were quarantined and
acclimated for a 7- day period before any procedures were con-
ducted and maintained in a specific pathogen-free condition in
the host laboratory.
Sprague-Dawley male rats weighing an average of 500 g were
obtained from Charles River Laboratories (Worcester, MA, USA).
2.2. Plasmid
Plasmid DNA containing a transgene encoding firefly luciferase
and tagged with the myc and DDK tags was used. This transgene
was purchased inserted into two different vectors: gWiz (Alde-
vron) and NTC9385R (Nature Technologies). Plasmid DNA was sus-
pended in sterile saline at 2 mg/mL. The endotoxin levels in both
plasmids were <0.1 EU/lg plasmid, confirmed by Aldevron and
Nature Technologies.
2.3. Surgical procedure
Anesthesia was initiated with 3% isoflurane inhalation in the
chamber and then animals were intubated with 16G IV catheter.
Respiration was maintained with a volume-controlled ventilator
at 70 breaths per minute. 2–3% isoflurane was used to maintain
anesthesia. A heated surgery table was used throughout the proce-
dure to support body temperature. Cardiac activity was monitored
the entire time with a three-lead electrocardiogram (Accusync
Medical Research Company, Milford, CT). Sterile technique was
used throughout the surgery and a 14-day prophylactic antibiotic
course of Trimethoprim Sulfa (SMZ-TMP) was given orally to pre-
vent infection.
The left ventricle of heart was exposed with a left thoracotomy
of the fifth intercostal space. After intramyocardial plasmid DNA
injections and gene transfer, the thoracic cavity was closed with
size 3–0 Monocryl suture with interrupted pattern. Any extra air
might have remained in the thoracic cavity was pulled out with
a 22G IV catheter to avoid pneumothorax. The muscle, skin and
connective tissue layers were closed with 5–0 Monocryl sutures.
Animals were then allowed to recover and continued to be moni-
tored until they were ambulatory. Carprofen was administered
before the surgery and given up to 48 h post operatively.
2.4. Gene electrotransfer
Luciferase encoding plasmid DNA was used to determine suc-
cess and quantity of gene expression. Animals were randomly
assigned to the groups for either pDNA injection + Gene Electro-
Transfer (GET) or pDNA injection only (IO). For the initial stages
of the study, the gWizLucMycDDK plasmid was used. In the
NanoplasmidTM portion of the study NTC9385R-Luc-Myc-DDK was
used.
Initially (Fig. 1), we used the same injection protocol as in our
previous studies injecting 100 lL plasmid DNA in one bolus into
the left ventricular myocardial wall, using a 30G needle on a
0.5 mL MonojectTM syringe. After the observations reported in
Fig. 1, we reduced the injection volume to 3 injections of 30 lL,
thus eliminating damage to the myocardium from the injection.
Cardioporation was perform using either a traditional bipolar
electrode with 4 needles that is inserted into the left ventricular
myocardium, or a 1 cm2 square platinum flat surface non-
invasive monopolar electrode, which requires a large grounding
plate, to be placed on the opposite flank (Supplemental Fig. 1).
The monopolar and bipolar groups described in this paper are dif-
ferentiated by the use of either electrode. Further information
regarding these electrodes is provided in another previously pub-
lished paper [23].
For GET groups using the bipolar 4-needle electrode, the nee-
dles were inserted into the myocardium of the ventricle. For GET
groups using the monopolar electrode, the electrode was then
placed onto the myocardial wall over the injection site. All pulses
were synchronized with the rise of the R-wave of the ECG. The
IO group received no electric pulses. For the bipolar needle elec-
trode group, 4 pulses were delivered at 60 V with a 20 ms pulse
length. For the monopolar groups, pulsing parameters varied. The
starting parameters (shown in Fig. 1), the applied voltage was
200 V, for 20 ms pulse length, with 4 pulses, as to mimic the pre-
viously established parameters for bipolar electrodes[10]. Follow-
ing damage and delivery assessments, monopolar condition was
altered to 4 pulses with 120 V applied voltage, and 100 ms pulse
length (shown in Figs. 3 and 4). Finally, further analysis led to
Fig. 2. Monopolar electrode reduces ventricular fibrillation and associated survival.
(A) Diagram showing a typical ECG pattern for rats. The shaded area indicates when
the beginning of each pulse was delivered, synchronized to the absolute refractory
period of the ECG. (B) Survival was significantly reduced for the bipolar group
when compared to the monopolar and injection only groups, due to
ventricular fibrillation. (C) Representative ECG for monopolar electrode group
during a single pulse. (D) Representative ECG for bipolar electrode group during
a single pulse, the purple dashed line indicates the start of a pulse.
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monopolar cardioporation pulsing parameters of 90 V applied,
100 ms pulse length with 4 pulses and NanoplasmidTM backbone
(Fig. 5).
2.5. Bioluminescence imaging
Animals were imaged for luciferase expression with the In-Vivo
Imaging System (IVIS) at 1, 2, 5, 7, 10, 14, 21, 28, 35, 42, 49, and
56 days after surgery (Fig. 1). For subsequent experiments, imaging
was performed on days 1 and 2, when peak expression is expected.
Animals were anesthetized with 3% isoflurane and 150 mg/kg
D-Luciferin, Potassium Salt (GoldBio, Cat#: LUCK) was applied sub-
cutaneously. Animals were imaged every 5 min until the peak
luciferase-luciferin reaction was achieved and then returned to
the cages and observed until they were fully recovered from the
anesthesia.
2.6. Immunofluorescence imaging
Hearts were harvested 48 h after surgery following the rats
being humanely euthanized, washed with saline and fixed in 4%
paraformaldehyde. After appropriate time of fixation, ventricular
portions of the hearts were sliced in 1.5 mm thickness and sent
to Idexx BioResearch (Columbia, MO) for paraffin embedding, cut-
ting, hematoxylin & eosin and Masson’s Trichrome staining.
Unstained serial sections were then processed for immunofluo-
rescence (IF) staining for DDK and cardiac-Troponin I counter-
staining. Briefly, slides were deparaffinized with Citrisolv clearing
agent (FisherScientific, Cat: 22–143-975) and rehydrated in EtOH
gradient series. Slides then buffered in PBST (BioWorld, Cat:
41620020–1), permeabilized with 0.25 %Triton-X and boiled with
AR6 Buffer (Perkin Elmer, Cat: AR6) for antigen retrieval. Then
the samples were blocked with 4% bovine serum albumin (Fisher
Scientific, Cat: BP1605100) and incubated with rabbit polyclonal
primary antibody against DDK (OriGene Technologies, Cat:
TA150078) and mouse monoclonal antibody against rat Cardiac
Troponin I (Abcam, Cat: ab10231) overnight at a 1:200 dilution.
Slides were washed the following day with PBST and blocked
again in 4% BSA. Secondary antibodies of highly cross adsorbed
Alexa Fluor 488 conjugated, goat anti-Rabbit IgG (Invitrogen, Cat:
A-11034) for DDK tag, and highly cross adsorbed Alexa Fluor 546
conjugated, Goat anti-Mouse IgG (Invitrogen, Cat: A-11030) for
Troponin I were used in addition to Spectral-DAPI (Perkin Elmer,
Cat: FP1490). Only secondary antibody was applied to the negative
control samples, without primary antibody. After 2 h of incubation
at ambient temperature, slides were then washed with PBST and
mounted with Vectashield hardset antifade mounting medium
(Vector Laboratories, Cat: H-1400).
Following IF staining, slides were imaged and analyzed with a
Leica DMi8 microscope.
3. Results
Initially, a 100 lL bolus injection into the ventricular myocar-
dium was followed by4 pulses of conditions of 200 V, and 20 ms
long, administered via the monopolar electrode. These conditions
were based on interpolation of previous data achieved with a 4-
needle bipolar electrode [10]. There was no significant difference
Fig. 3. Cardioporation induces minimal damage to myocardium. (A) Damage assessment shows no significant difference between all three groups. Example trichrome
staining for IO (B), Bipolar electrode (C) and Monopolar electrode (D).














Fig. 4. Gene expression levels, transfection efficiency, and distribution measured by bioluminescence imaging and IF show minimal difference between monopolar and
bipolar cardioporation. Gene expression levels per group ( monopolar, bipolar, and injection only) measured by bioluminescence imaging (A). Transfection efficiency
measured by cell counts from IF data, p < 0.026 (B). IF staining within the myocardium for the monopolar (C) and 4-needle bipolar electrodes (D).
Fig. 5. Reduction of vector backbone size significantly improved gene expression levels. Gene expression levels as measured by bioluminescence ( NanoplasmidTM,
monopolar, bipolar, and injection only groups, A). IF of the myocardium from the NanoplasmidTM group (B).
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in gene expression levels between monopolar cardioporation and
injection only groups (Fig. 1). There was considerable damage to
the myocardium 2 days after gene delivery, observed in trichrome
images, which occupied nearly one half of the ventricular wall
(data not shown). The damage was present in both IO andMonopo-
lar cardioporation groups, thus was attributed to plasmid DNA
injection.
For the next set of experiments, the plasmid DNA injection was
adjusted to 3 injections of 30 lL, which resulted in no significant
damage to the myocardium (Fig. 3A-B). We directly compared
the bipolar 4-needle electrode condition (60 V, 20 ms, 4 pulses)
to the monopolar electrode pulsing conditions of 120 V applied,
100 ms pulse length with 4 pulses. The pulses of the bipolar and
monopolar electrode groups were synchronized with the rise of
the R-wave of the ECG (Fig. 2). The monopolar electrode and IO
groups had 100% survival rates when compared to the bipolar elec-
trode group. This was largely due to ventricular fibrillation during
pulsing that was observed only the bipolar electrode group. Ven-
tricular fibrillation was not observed at all for any of the monopo-
lar conditions used for this study. Fig. 2B-C shows a typical ECG
signal following one pulse administration with the bipolar and
monopolar electrodes, with ventricular fibrillation observed for
the bipolar group.
Damage assessment from tiled trichrome images of heart sec-
tions harvested on day 2 showed no significant difference in terms
of tissue damage between the monopolar, the bipolar and the IO
groups (Fig. 3), based on one-way ANOVA. There was a significant
difference in gene expression levels measured by bioluminescence
between the monopolar conditions, bipolar conditions or injection
only conditions (Fig. 4A). However, in terms of transfection effi-
ciency, measured by the number of DDK positive cardiomyocytes
(Fig. 4B-D), the monopolar group had significantly higher transfec-
tion efficiency.
A 2-fold smaller plasmid vector (NanoplasmidTM) that was engi-
neered to provide high expression, particularly when compared to
the gWiz vector [24]. When measured by bioluminescence, the
NanoplasmidTM vector delivered by monopolar cardioporation
(90 V, 100 ms pulses, 4 pulses) had significantly higher levels of
gene expression then IO, gWiz vector delivering the same insert
with a monopolar configuration (Fig. 5).
4. Discussion
We would like to report that while it is common to report a
100 lL injection into rat ventricular myocardium, according to
our findings, there injections cause significant damage to the myo-
cardium, may skew results and should be avoided. Fig. 1 indicates
that while naked plasmid DNA injection leads to some expression
in ventricular myocardium, the damage caused by the large vol-
ume of the injection, masked any potential benefit form cardiopo-
ration for efficient gene delivery. Once damage from the injection
itself was mitigated, monopolar cardioporation optimization could
readily be evaluated.
Our results suggest that the monopolar electrode configuration
was able to address the issue of ventricular fibrillation that was
present when using the bipolar 4-needle electrode configuration.
This resulted in 100% survival in the monopolar electrode group,
while the bipolar electrode resulted in a drop in survival due to
induction of ventricular fibrillation (Fig. 2). Damage from bipolar
and monopolar cardioporation was minimal as can be seen in rep-
resentative trichrome images (Fig. 3B-D) and not significantly
higher than IO (Fig. 3A) as evaluated by a one-way ANOVA.
The gene expression results (Fig. 4) results with the gWizLuc-
MycDDK plasmid show no significant difference between the GET
and IO groups in gene expression levels. The transfection efficiency
is significantly higher with the monopolar electrode use. To
address marginal differences in gene expression, we utilized a plas-
mid DNA backbone engineered to provide higher gene expression
levels, by reducing the size of the vector [24]. The NanoplasmidTM
was able to achieve significantly higher gene expression levels at
day 2 despite the lower voltage used when compared to the gWi-
zLucMycDDK group (Fig. 5). This is beneficial, as lowering voltage
during GET has been shown to reduce tissue damage [25]. For fur-
ther research using therapeutic genes, we plan to use the same
NanoplasmidTM vector to deliver VEGF-B. By utilizing both the
NanoplasmidTM and monopolar electrode, we were able to optimize
cardioporation in terms of safety from ventricular fibrillation and
tissue damage, as well as achieving enhanced levels of gene
expression.
5. Conclusion
We have improved many parameters of our cardioporation
method for efficient gene delivery to the myocardium. The
monopolar cardioporation protocol was shown safer than previ-
ously optimized protocol utilizing a bipolar 4-needle electrode,
with no observed ventricular fibrillation occurring. Monopolar car-
dioporation further showed comparable expression levels and
minimal tissue damage. The monopolar configuration is, therefore,
advantageous over the traditional bipolar approach and may
expand clinical utility in the heart. Additionally, by reducing the
plasmid vector size, we were able to further improve gene expres-
sion levels, while further lowering the applied voltage. Monopoloar
cardioporation of nanoplasmid DNA is thus a more efficient, safer
and potentially more effective method for gene electrotransfer to
the heart, which presents opportunity for effector gene delivery
to induce therapeutic cardiac regeneration in the future.
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